Cargando…
Use of Rapamycin in a Patient With Juvenile Myelomonocytic Leukemia: A Case Report
The relapse rate for children with juvenile myelomonocytic leukemia (JMML) status post hematopoietic stem cell transplantation (HSCT) approaches 50% within 5 years. Graft-versus-leukemia (GVL) is thought to play important role in the treatment of JMML. For this reason, careful management of immunosu...
Autores principales: | Upadhyay, Shivani Y., De Oliveira, Satiro N., Moore, Theodore B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593212/ https://www.ncbi.nlm.nih.gov/pubmed/28959694 http://dx.doi.org/10.1177/2324709617728528 |
Ejemplares similares
-
The Genomic Landscape of Juvenile Myelomonocytic Leukemia
por: Stieglitz, Elliot, et al.
Publicado: (2015) -
Current Treatment of Juvenile Myelomonocytic Leukemia
por: Mayerhofer, Christina, et al.
Publicado: (2021) -
Management of Two Juvenile Myelomonocytic Leukemia Patients According to Clinical and Genetic Features
por: Tüfekçi, Özlem, et al.
Publicado: (2015) -
Leukemia cutis in a child with juvenile myelomonocytic leukemia presenting with Sweet syndrome–like lesions and a history of multiple juvenile xanthogranulomas
por: Quek, Chrystie Wan Ning, et al.
Publicado: (2020) -
Cerebral localization of chronic myelomonocytic leukemia: a case report
por: Haméon, Clémence, et al.
Publicado: (2021)